DNA testing company Natera Inc (NASDAQ:NTRA) reported on Monday that it has received positive coverage for the Prospera donor-derived cell-free DNA (dd-cfDNA) test from Noridian, a Medicare Administrative Contractor (MAC).

Noridian is developing a generic policy for dd-cfDNA testing that will include multiple commercially available tests under one consistent policy and accordingly Prospera's coverage will be under the new policy in the future along with others.

Natera added that it received early success in the ProActive study, which has activated 18 of the top transplant centres and enrolled 145 patients, as well as received tests from 45% of the top 50 and 37% of the top 100 transplant centres by volume in early access programme.

The Prospera test utilises the company's core single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test measures the fraction of donor-derived cell-free DNA (dd-cfDNA) in the recipient's blood.